{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:38:05Z","timestamp":1792597085942,"version":"4.5.0"},"reference-count":12,"publisher":"MyJove Corporation","issue":"222","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/68957","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T23:00:33Z","timestamp":1755039633000},"source":"Crossref","is-referenced-by-count":3,"title":["Development of Drug-resistant Cell Lines for Experimental Procedures"],"prefix":"10.3791","author":[{"given":"Suguru","family":"Kadomoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Shelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan T.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","first-page":"28","type":"journal-article","article-title":"Mechanisms and insights into drug resistance in cancer","volume":"4","author":"Zahreddine","year":"2013","unstructured":"Zahreddine, H., Borden, K L. Mechanisms and insights into drug resistance in cancer. Fron Pharmacol. 4, 28 (2013).","journal-title":"Fron Pharmacol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"891652","DOI":"10.3389\/fonc.2022.891652","type":"journal-article","article-title":"Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches","volume":"12","author":"Emran","year":"2022","unstructured":"Emran, T. B. et al. Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches. Fron Oncol. 12, 891652 (2022).","journal-title":"Fron Oncol"},{"issue":"9","key":"ref3","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/pros.20581","type":"journal-article","article-title":"The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines","volume":"67","author":"Takeda","year":"2007","unstructured":"Takeda, M., e al. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate. 67 (9), 955-967 (2007).","journal-title":"Prostate"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-24-2771","type":"journal-article","article-title":"TOP1 mutations and cross-resistance to antibody-drug conjugates in patients with metastatic breast cancer","volume":"31","author":"Abelman","year":"2025","unstructured":"Abelman, R. O. et al. TOP1 mutations and cross-resistance to antibody-drug conjugates in patients with metastatic breast cancer. Cli Cancer Res. 31 (10), 1966-1974 (2025).","journal-title":"Cli Cancer Res"},{"key":"ref5","first-page":"40","type":"journal-article","article-title":"In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies","volume":"4","author":"McDermott","year":"2014","unstructured":"McDermott, M., e al. In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies. Fron Oncol. 4, 40 (2014).","journal-title":"Fron Oncol"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.tiv.2008.04.005","type":"journal-article","article-title":"Development of taxane resistance in a panel of human lung cancer cell lines","volume":"22","author":"Breen","year":"2008","unstructured":"Breen, L., Murphy, L., Keenan, J., Clynes, M. Development of taxane resistance in a panel of human lung cancer cell lines. Toxico In Vitro. 22 (5), 1234-1241 (2008).","journal-title":"Toxico In Vitro"},{"key":"ref7","type":"book","volume-title":"IC50 calculator","author":"Bioquest","year":"2025","unstructured":"AA Bioquest. IC50 calculator. AA Bioquest. https:\/\/www.aatbio.com\/tools\/ic50-calculator (2025)."},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0169-5002(01)00430-5","type":"journal-article","article-title":"Characterization of non small-cell lung cancer cell lines established before and after chemotherapy","volume":"35","author":"Kawai","year":"2002","unstructured":"Kawai, H., e al. Characterization of non small-cell lung cancer cell lines established before and after chemotherapy. Lun Cancer. 35 (3), 305-314 (2002).","journal-title":"Lun Cancer"},{"issue":"23","key":"ref9","first-page":"6891","type":"journal-article","article-title":"Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up","volume":"48","author":"Berendsen","year":"1988","unstructured":"Berendsen, H. H. et al. Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up. Cance Res. 48 (23), 6891-6899 (1988).","journal-title":"Cance Res"},{"issue":"16","key":"ref10","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1158\/0008-5472.CAN-09-1178","type":"journal-article","article-title":"Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma","volume":"69","author":"Sakai","year":"2009","unstructured":"Sakai, W., e al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cance Res. 69 (16), 6381-6386 (2009).","journal-title":"Cance Res"},{"issue":"9","key":"ref11","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1158\/1541-7786.MCR-20-0051","type":"journal-article","article-title":"Single-cell transcriptomics analysis identifies nuclear protein 1 as a regulator of docetaxel resistance in prostate cancer cells","volume":"18","author":"Schnepp","year":"2020","unstructured":"Schnepp, P. M. et al. Single-cell transcriptomics analysis identifies nuclear protein 1 as a regulator of docetaxel resistance in prostate cancer cells. Mo Cancer Res. 18 (9), 1290-1301 (2020).","journal-title":"Mo Cancer Res"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3390\/biomedicines12030547","type":"journal-article","article-title":"New insights into chemoresistance mediated by Mdm2 inhibitors: the benefits of targeted therapy over common cytostatics","volume":"12","author":"Grigoreva","year":"2024","unstructured":"Grigoreva, T., Sagaidak, A., Novikova, D., Tribulovich, V. New insights into chemoresistance mediated by Mdm2 inhibitors: the benefits of targeted therapy over common cytostatics. Biomedicines. 12 (3), 547 (2024).","journal-title":"Biomedicines"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/app.jove.com\/t\/68957\/development-of-drug-resistant-cell-lines-for-experimental-procedures","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:39:31Z","timestamp":1792593571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/68957\/development-of-drug-resistant-cell-lines-for-experimental-procedures"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":12,"journal-issue":{"issue":"222","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3791\/68957","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}